BDS' current core technologies in the marketplace are:

> DR CALUX^® for dioxins and dioxin-like PCBs;
> ERalpha CALUX^® / anti-ERalpha CALUX^® for estrogens and pseudo estrogens;
> ERbeta CALUX^® / anti-ERbeta CALUX^® for estrogens and pseudo estrogens;
> AR CALUX^® / anti-AR CALUX^®  for androgen hormones;
> PR CALUX^® / anti-PR CALUX^®;
> GR CALUX^® / anti-GR CALUX^®;
> TRbeta CALUX^®;
> PPARgamma2 CALUX^®;
> RAR CALUX^®;
> p53 CALUX^® (U2OS);
> p53 CALUX^® (HepG2);
> p21 CALUX^®;
> Nrf2 CALUX^®;
> Control CALUX^®;
> NFKB CALUX^®;
> PAH CALUX^®.

For more information on our technologies click here. For new assays and developments contact us


BioDetection Systems offers its CALUX^® technology in two principle ways:
1.  Licensing of CALUX^® technology for use in-house or to offer to third parties;
2.  Contract analytical CALUX^® work including ISO17025 analysis

Contact us to discuss your requirements


We also provide related and other services including:
> Consultancy
> New and novel receptor based bioassays
> Reference materials
> Others

See other services for more details